Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002505 · ClinicalTrials.gov registry record · Phase 2
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002505: Completed Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
NCT00002505 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002505, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.
Interventions
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant interferon gamma
- BIOLOGICAL tumor cell lysate vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
What the finished NCT00002505 record still lists
NCT00002505 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00002505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002505 about?
NCT00002505 is a clinical study titled "Tumor Cell Vaccine in Treating Patients With Advanced Cancer". RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cance...
What is the current status of trial NCT00002505?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00002505?
The interventions under investigation include: filgrastim (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL), tumor cell lysate vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002505?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia